Mercia Technologies, a Midlands-based investment group building, funding and commercialising technology businesses in the UK, is pleased to announce a new direct investment of up to £2.0 million in Oxford Genetics Ltd. Through its expertise in DNA design, Oxford Genetics’ focus is on protein expression optimisation and cell line development to provide bespoke solutions for research, therapeutic and clinical needs within the pharmaceutical industry.
You can read the full stock exchange announcement here.
To find out more, visit the Oxford Genetics website.